Is Travere Therapeutics, Inc. (TVTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.1% / 30% | 12.8% / 30% | 3.2% / 30% | 2.59% / 5% | ✓ HALAL |
| DJIM | 13.1% / 33% | 12.8% / 33% | 3.2% / 33% | 2.59% / 5% | ✓ HALAL |
| MSCI | 54.3% / 33% | 53.3% / 33% | 13.2% / 33% | 2.59% / 5% | ✗ NOT HALAL |
| S&P | 13.1% / 33% | 12.8% / 33% | 3.2% / 33% | 2.59% / 5% | ✓ HALAL |
| FTSE | 54.3% / 33% | 53.3% / 33% | 13.2% / 50% | 2.59% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 55.9% | |
| Operating Margin | -25.0% | |
| Net Margin | -5.2% | |
| Return on Equity (ROE) | -57.8% | |
| Return on Assets (ROA) | -6.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $38M |
| Free Cash Flow | -$20M |
| Total Debt | $329M |
| Debt-to-Equity | 286.3 |
| Current Ratio | 2.7 |
| Total Assets | $605M |
Price & Trading
| Last Close | $27.92 |
| 50-Day MA | $29.08 |
| 200-Day MA | $26.21 |
| Avg Volume | 2.0M |
| Beta | 0.9 |
|
52-Week Range
$12.91
| |
About Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Purification Calculator
As a halal stock with 2.59% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Travere Therapeutics, Inc. (TVTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Travere Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Travere Therapeutics, Inc.'s debt ratio?
Travere Therapeutics, Inc.'s debt ratio is 13.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 54.3%.
Does Travere Therapeutics, Inc. require dividend purification?
Yes, Travere Therapeutics, Inc. has an impermissible income ratio of 2.59%, which means 2.59% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Travere Therapeutics, Inc.'s key financial metrics?
Travere Therapeutics, Inc. has a market capitalization of $2.5B, and revenue of $491M. The company maintains a gross margin of 55.9% and a net margin of -5.2%. Return on equity stands at -57.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.